Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept after Vitrectomy for Early PDR
NCT03426540Phase 1Completed
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Jan 2017
- Primary completion
- Mar 2018
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1, randomised, open-label trial of conbercept in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Tianjin Medical University Eye Hospital. Primary endpoint: Best Corrected Visual Acuity at 24 weeks. Started Jan 2017; status: completed.
02
Drugs
conbercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT03426540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03426540.